WINT
Windtree Therapeutics, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mar. 7, 2012, 11:38 AM

    Discovery Labs (DSCO +17.9%) could be acquired, speculates Roth Capital. Following the approval of its synthetic surfactant, Surfaxin, by the FDA, Roth says the company could sell itself, or obtain a partner. It raises its target on the shares to $10 from $6 while maintaining its Buy rating.

    | Mar. 7, 2012, 11:38 AM | 3 Comments